Researchers Submit Patent Application, "Methods of Using 4-Amino-N-[4-(Methoxymethyl)Phenyl]-7-(1-Methylcyclopropyl)-6-(3-Morpholinoprop-1-YN-1-YL)-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carboxamide for the Treatment of Tumors", for Approval (USPTO 2024.

A patent application has been submitted for a new method of using a compound called HM06/TAS0953 to treat tumors. The compound is a selective inhibitor of the RET gene, which is involved in the development and progression of various cancers. It has shown promising results in preclinical models, inhibiting the growth of lung cancer cells with RET gene abnormalities and crossing into the brain to target tumors. The method involves administering the compound orally at varying dosages, ranging from 40 mg to 3000 mg per day, and can be used for patients with brain and/or leptomeningeal metastases as well as solid tumors. The method is effective for both symptomatic and asymptomatic metastases and may be beneficial for patients resistant to other treatments. [Extracted from the article]